Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""The oncologist [Oncologist] NLMUID: 9607837"" wg kryterium: JN


Tytuł :
Effects of an interprofessional communication approach on support needs, quality of life and mood of advanced lung cancer patients: a randomized trial.
Autorzy :
Krug K; University Hospital Heidelberg, Dept. of General Practice and Health Services Research.
Bossert J; University Hospital Heidelberg, Dept. of General Practice and Health Services Research.; University Hospital Heidelberg, Thoracic Clinic, Dept. of Thoracic Oncology, Translational Lung Research Center Heidelberg (TLRC-H), German Center for Lung Research (DZL).
Deis N; University Hospital Heidelberg, Thoracic Clinic, Dept. of Thoracic Oncology, Translational Lung Research Center Heidelberg (TLRC-H), German Center for Lung Research (DZL).
Krisam J; University Hospital Heidelberg, Institute of Medical Biometry and Informatics.
Villalobos M; University Hospital Heidelberg, Thoracic Clinic, Dept. of Thoracic Oncology, Translational Lung Research Center Heidelberg (TLRC-H), German Center for Lung Research (DZL).
Siegle A; University Hospital Heidelberg, Thoracic Clinic, Dept. of Thoracic Oncology, Translational Lung Research Center Heidelberg (TLRC-H), German Center for Lung Research (DZL).
Jung C; University Hospital Heidelberg, Thoracic Clinic, Dept. of Thoracic Oncology, Translational Lung Research Center Heidelberg (TLRC-H), German Center for Lung Research (DZL).; Medical School Berlin, Calandrellistr. 1-9, 12247, Berlin, Germany.
Hagelskamp L; University Hospital Heidelberg, Thoracic Clinic, Dept. of Thoracic Oncology, Translational Lung Research Center Heidelberg (TLRC-H), German Center for Lung Research (DZL).
Unsöld L; University Hospital Heidelberg, Thoracic Clinic, Dept. of Thoracic Oncology, Translational Lung Research Center Heidelberg (TLRC-H), German Center for Lung Research (DZL).
Jünger J; German National Institute for State Examinations in Medicine, Pharmacy and Psychotherapy, Mainz.
Thomas M; University Hospital Heidelberg, Thoracic Clinic, Dept. of Thoracic Oncology, Translational Lung Research Center Heidelberg (TLRC-H), German Center for Lung Research (DZL).
Wensing M; University Hospital Heidelberg, Dept. of General Practice and Health Services Research.
Pokaż więcej
Źródło :
The oncologist [Oncologist] 2021 Apr 16. Date of Electronic Publication: 2021 Apr 16.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Efficacy and Safety of Trametinib in Non-V600 BRAF Mutant Melanoma: A Phase I Study.
Autorzy :
Nebhan CA; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Johnson DB; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Sullivan RJ; Massachusetts General Hospital, Boston, Massachusetts, USA.
Amaria RN; Department of Cutaneous Oncology, MD Anderson Cancer Center, Houston, Texas, USA.
Flaherty KT; Massachusetts General Hospital, Boston, Massachusetts, USA.
Sosman JA; Department of Medicine, Robert H. Lurie Cancer Center, Northwestern University, Chicago, Illinois, USA.
Davies MA; Department of Cutaneous Oncology, MD Anderson Cancer Center, Houston, Texas, USA.
Pokaż więcej
Źródło :
The oncologist [Oncologist] 2021 Apr 16. Date of Electronic Publication: 2021 Apr 16.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Salvage treatment using anti-PD-1/CTLA-4 immunotherapy after failure of neoadjuvant chemotherapy in microsatellite instable gastroesophageal carcinoma.
Autorzy :
Klein O; Olivia Newton-John Cancer Research Institute, Melbourne, Australia.
Brown WA; Department of Surgery, Alfred Health, Melbourne, Australia.
Saxon S; Department of Anatomical Pathology, Alfred Health, Melbourne, Australia.
Haydon A; Department of Medical Oncology, Alfred Health, Australia.
Pokaż więcej
Źródło :
The oncologist [Oncologist] 2021 Apr 15. Date of Electronic Publication: 2021 Apr 15.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Impact of cancer history on outcomes among hospitalized COVID-19 patients.
Autorzy :
Klein IA; Dana-Farber Cancer Institute, Boston, MA.
Rosenberg SM; Dana-Farber Cancer Institute, Boston, MA.
Reynolds KL; Massachusetts General Hospital, Boston, MA.
Zubiri L; Massachusetts General Hospital, Boston, MA.
Rosovsky R; Massachusetts General Hospital, Boston, MA.
Piper-Vallillo AJ; Massachusetts General Hospital, Boston, MA.
Gao X; Massachusetts General Hospital, Boston, MA.
Boland G; Massachusetts General Hospital, Boston, MA.
Bardia A; Massachusetts General Hospital, Boston, MA.
Gaither R; Dana-Farber Cancer Institute, Boston, MA.
Freeman H; Dana-Farber Cancer Institute, Boston, MA.
Kirkner GJ; Dana-Farber Cancer Institute, Boston, MA.
Rhee C; Brigham and Women's Hospital, Boston, MA.; Department of Population Medicine, Harvard Medical School, Boston, MA.
Klompas M; Brigham and Women's Hospital, Boston, MA.; Department of Population Medicine, Harvard Medical School, Boston, MA.
Baker MA; Brigham and Women's Hospital, Boston, MA.; Department of Population Medicine, Harvard Medical School, Boston, MA.
Wadleigh M; Dana-Farber Cancer Institute, Boston, MA.
Winer EP; Dana-Farber Cancer Institute, Boston, MA.
Kotton CN; Massachusetts General Hospital, Boston, MA.
Partridge AH; Dana-Farber Cancer Institute, Boston, MA.
Pokaż więcej
Źródło :
The oncologist [Oncologist] 2021 Apr 15. Date of Electronic Publication: 2021 Apr 15.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
COVID-19 Pandemic Effects on Breast Cancer Diagnosis in Croatia: A Population- and Registry-Based Study.
Autorzy :
Vrdoljak E; Department of Oncology, Clinical Hospital Centre Split, School of Medicine, University of Split, Split, Croatia.
Balja MP; Department of Pathology, Clinical Hospital Centre Sisters of Mercy, Zagreb, Croatia.
Marušić Z; Department of Pathology, Clinical Hospital Centre Zagreb, Zagreb, Croatia.
Avirović M; Department of Pathology, Clinical Hospital Centre Rijeka, Rijeka, Croatia.
Blažičević V; Department of Pathology, Clinical Hospital Centre Osijek, Osijek, Croatia.
Tomasović Č; Department of Pathology, Clinical Hospital Dubrava, Zagreb, Croatia.
Čerina D; Department of Oncology, Clinical Hospital Centre Split, School of Medicine, University of Split, Split, Croatia.
Bajić Ž; Research unit 'Dr. Mirko Grmek,' University Psychiatric Hospital 'Sveti Ivan,' Zagreb, Croatia.
Miše BP; Department of Oncology, Clinical Hospital Centre Split, School of Medicine, University of Split, Split, Croatia.
Lovasić IB; Department of Oncology, Clinical Hospital Centre Rijeka, Rijeka, Croatia.
Flam J; Department of Oncology, Clinical Hospital Centre Osijek, Osijek, Croatia.
Tomić S; Department of Pathology, University Hospital of Split, Split, Croatia.
Pokaż więcej
Źródło :
The oncologist [Oncologist] 2021 Apr 15. Date of Electronic Publication: 2021 Apr 15.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Antibiotics and Imiquimod for CTCL in Veterans: A Patient Population with Agent Orange Exposure.
Autorzy :
Del Guzzo CA; Department of Dermatology, University of Pennsylvania, Philadelphia, PA.
Kojadinovic A; Hematology and Oncology, James J. Peters Veterans Affairs Medical Center, Bronx, NY.
Vinnakota RR; Department of Medicine, , St. Luke's Hospitalist Group, Easton, PA.
Geskin LJ; Department of Dermatology, Columbia University Medical Center, New York, NY.
Newman JC; Department of Dermatology, Columbia University Medical Center, New York, NY.; Department of Dermatology, James J. Peters Veterans Affairs Medical Center, Bronx, NY.
Langhoff E; Department of Nephrology, Mt. Sinai School of Medicine, New York, NY.
Park YA; Hematology and Oncology, James J. Peters Veterans Affairs Medical Center, Bronx, NY.; Department of Hematology and Oncology, Columbia University Medical Center, New York, NY.
Bates SE; Department of Hematology and Oncology, Columbia University Medical Center, New York, NY.
Dana AN; Department of Dermatology, Columbia University Medical Center, New York, NY.; Department of Dermatology, James J. Peters Veterans Affairs Medical Center, Bronx, NY.; Bellaire Dermatology, Houston, TX.
Pokaż więcej
Źródło :
The oncologist [Oncologist] 2021 Apr 14. Date of Electronic Publication: 2021 Apr 14.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Safety and Efficacy of First-Line Pembrolizumab in Black Patients with Metastatic Non-Small-Cell Lung Cancer.
Autorzy :
Peravali M; MedStar Washington Hospital Center, Washington, DC.
Ahn J; Department of Biostatistics, Bioinformatics, and Biomathematics, Georgetown University, Washington, DC.
Chen K; MedStar Franklin Square Medical Center, Baltimore, MD.
Rao S; MedStar Franklin Square Medical Center, Baltimore, MD.
Veytsman I; MedStar Washington Hospital Center, Washington, DC.
Liu SV; MedStar Georgetown University Hospital, Washington, DC.
Kim C; MedStar Georgetown University Hospital, Washington, DC.
Pokaż więcej
Źródło :
The oncologist [Oncologist] 2021 Apr 12. Date of Electronic Publication: 2021 Apr 12.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Trend in stereotactic radiation therapy use for management of bone and brain metastases in patients with renal cell carcinoma in Australia.
Autorzy :
Ong WL; Department of Radiation Oncology, Peter MacCallum Cancer Centre, Australia.; Department of Radiation Oncology, Olivia Newton-John Cancer Wellness and Research Centre, Austin Health, Australia.; School of Clinical Medicine, University of Cambridge, UK.; Department of Epidemiology and Preventive Medicine, Monash University, Australia.
Siva S; Department of Radiation Oncology, Peter MacCallum Cancer Centre, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Australia.
Milne RL; Cancer Epidemiology Division, Cancer Council Victoria, Australia.; Centre for Epidemiology and Biostatistics, School of Population and Global Health, University of Melbourne, Australia.; Precision Medicine, School of Clinical Sciences, Monash Health, Monash University, Australia.
Foroudi F; Department of Radiation Oncology, Olivia Newton-John Cancer Wellness and Research Centre, Austin Health, Australia.
Millar JL; Alfred Health Radiation Oncology Services, Australia.; Central Clinical School, Monash University, Australia.
Pokaż więcej
Źródło :
The oncologist [Oncologist] 2021 Apr 12. Date of Electronic Publication: 2021 Apr 12.
Typ publikacji :
Letter
Opinia redakcyjna
Tytuł :
Prevalence and Tolerance of Prognostic Uncertainty among Thoracic Oncologists.
Autorzy :
Habib AR; Division of Population Sciences, Dana-Farber Cancer Institute, Boston, MA.; Department of Internal Medicine, University of California San Francisco, San Francisco, CA.
Chen R; Division of Population Sciences, Dana-Farber Cancer Institute, Boston, MA.
Magnavita ES; Division of Population Sciences, Dana-Farber Cancer Institute, Boston, MA.
Jaung T; Division of Population Sciences, Dana-Farber Cancer Institute, Boston, MA.
Awad MM; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA.
Odejide O; Division of Population Sciences, Dana-Farber Cancer Institute, Boston, MA.
Abel GA; Division of Population Sciences, Dana-Farber Cancer Institute, Boston, MA.
Pokaż więcej
Źródło :
The oncologist [Oncologist] 2021 Apr 12. Date of Electronic Publication: 2021 Apr 12.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Relationship of HER2 alteration and MSI status in colorectal adenocarcinoma.
Autorzy :
Qiu MZ; Department of Medical Oncology, Sun Yat-Sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, 651 Dongfeng Road East, Guangzhou, 510060, P. R. China.
He CY; Department of Molecular Diagnostics, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, P. R. China.
Yang XH; Department of Molecular Diagnostics, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, P. R. China.
Yang LQ; Department of Experimental Research, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, P. R. China.
Lin JZ; Department of Colorectal Surgery, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, P. R. China.
Zhou DL; Department of Molecular Diagnostics, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, P. R. China.
Long YK; Department of Molecular Diagnostics, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, P. R. China.
Guan WL; Department of Medical Oncology, Sun Yat-Sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, 651 Dongfeng Road East, Guangzhou, 510060, P. R. China.
Jin Y; Department of Medical Oncology, Sun Yat-Sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, 651 Dongfeng Road East, Guangzhou, 510060, P. R. China.
Li YH; Department of Medical Oncology, Sun Yat-Sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, 651 Dongfeng Road East, Guangzhou, 510060, P. R. China.
Wang FH; Department of Medical Oncology, Sun Yat-Sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, 651 Dongfeng Road East, Guangzhou, 510060, P. R. China.
Yang DJ; Department of Experimental Research, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, P. R. China.
Xu RH; Department of Medical Oncology, Sun Yat-Sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, 651 Dongfeng Road East, Guangzhou, 510060, P. R. China.
Pokaż więcej
Źródło :
The oncologist [Oncologist] 2021 Apr 12. Date of Electronic Publication: 2021 Apr 12.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Bevacizumab Combined with S-1 and Raltitrexed for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies: A Phase II Study.
Autorzy :
Chen Y; Department of Abdominal Cancer, West China Hospital, West China Medical School, Sichuan University, Chengdu, People's Republic of China.
Zhou YW; Department of Biotherapy, Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu, People's Republic of China.
Cheng K; Department of Abdominal Cancer, West China Hospital, West China Medical School, Sichuan University, Chengdu, People's Republic of China.
Li ZP; Department of Abdominal Cancer, West China Hospital, West China Medical School, Sichuan University, Chengdu, People's Republic of China.
Luo DY; Department of Abdominal Cancer, West China Hospital, West China Medical School, Sichuan University, Chengdu, People's Republic of China.
Qiu M; Department of Abdominal Cancer, West China Hospital, West China Medical School, Sichuan University, Chengdu, People's Republic of China.
Li Q; Department of Abdominal Cancer, West China Hospital, West China Medical School, Sichuan University, Chengdu, People's Republic of China.
Wang X; Department of Abdominal Cancer, West China Hospital, West China Medical School, Sichuan University, Chengdu, People's Republic of China.
Shen YL; Department of Abdominal Cancer, West China Hospital, West China Medical School, Sichuan University, Chengdu, People's Republic of China.
Cao D; Department of Abdominal Cancer, West China Hospital, West China Medical School, Sichuan University, Chengdu, People's Republic of China.
Yang Y; Department of Abdominal Cancer, West China Hospital, West China Medical School, Sichuan University, Chengdu, People's Republic of China.
Bi F; Department of Abdominal Cancer, West China Hospital, West China Medical School, Sichuan University, Chengdu, People's Republic of China.
Liu JY; Department of Biotherapy, Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu, People's Republic of China.
Gou HF; Department of Abdominal Cancer, West China Hospital, West China Medical School, Sichuan University, Chengdu, People's Republic of China.
Pokaż więcej
Źródło :
The oncologist [Oncologist] 2021 Apr 08. Date of Electronic Publication: 2021 Apr 08.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3. In Reply to Badoui, et al.
Autorzy :
Rugo HS; University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA.
Huober J; Universitätsklinikum Ulm, Ulm, Germany.
Garcia-Saenz JA; Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Hospital Clínico San Carlos, Madrid, Spain.
Masuda N; National Hospital Organization Osaka National Hospital, Osaka, Japan.
Sohn JH; Yonsei Cancer Center, Seoul, Republic of Korea.
Andre VAM; Eli Lilly and Company, Paris, France.
Barriga S; Eli Lilly and Company, Madrid, Spain.
Cox J; Eli Lilly and Company, Surrey, United Kingdom.
Goetz M; Mayo Clinic, Rochester, Minnesota, USA.
Pokaż więcej
Źródło :
The oncologist [Oncologist] 2021 Apr 07. Date of Electronic Publication: 2021 Apr 07.
Typ publikacji :
Letter
Opinia redakcyjna
Tytuł :
Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR).
Autorzy :
Choueiri TK; Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Zakharia Y; University of Iowa, Holden Comprehensive Cancer Center, Iowa City, Iowa, USA.
Pal S; City of Hope National Medical Center, Duarte, California, USA.
Kocsis J; Bács-Kiskun County Hospital, Oncoradiology Center, Kecskemét, Hungary.
Pachynski R; Division of Oncology, Washington University School of Medicine, St. Louis, Missouri, USA.
Poprach A; Department of Comprehensive Cancer Care and Faculty of Medicine, Masaryk Memorial Cancer Institute and Masaryk University, Brno, Czech Republic.
Nixon AB; Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA.
Liu Y; Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA.
Starr M; Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA.
Lyu J; Graduate Group in Biostatistics, University of California Davis, Davis, California, USA.
Owzar K; Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina, USA.
deShazo M; Division of Hematology/Oncology, Department of Internal Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Lara P; University of California, Davis Medical Center, Sacramento, California, USA.
Geczi L; Országos Onkológiai Intézet, Budapest, Hungary.
Ho TH; Division of Hematology/Oncology, Mayo Clinic Arizona, Scottsdale, Arizona, USA.
Walsh M; Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Adams B; TRACON Pharmaceuticals, Inc., San Diego, California, USA.
Robertson L; TRACON Pharmaceuticals, Inc., San Diego, California, USA.
Darif M; TRACON Pharmaceuticals, Inc., San Diego, California, USA.
Theuer C; TRACON Pharmaceuticals, Inc., San Diego, California, USA.
Agarwal N; Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA.
Pokaż więcej
Źródło :
The oncologist [Oncologist] 2021 Apr 07. Date of Electronic Publication: 2021 Apr 07.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Analysis of real-world data to investigate the impact of race and ethnicity on response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers.
Autorzy :
Ayers KL; Sema4, a Mount Sinai Venture, 333 Ludlow Street, Stamford, CT, 06902, USA.
Mullaney T; Sema4, a Mount Sinai Venture, 333 Ludlow Street, Stamford, CT, 06902, USA.
Zhou X; Sema4, a Mount Sinai Venture, 333 Ludlow Street, Stamford, CT, 06902, USA.
Liu JJ; Sema4, a Mount Sinai Venture, 333 Ludlow Street, Stamford, CT, 06902, USA.; Illinois CancerCare, 8940 N Wood Sage Rd, Peoria, IL, 61615.
Lee K; Sema4, a Mount Sinai Venture, 333 Ludlow Street, Stamford, CT, 06902, USA.
Ma M; Sema4, a Mount Sinai Venture, 333 Ludlow Street, Stamford, CT, 06902, USA.
Jones S; Sema4, a Mount Sinai Venture, 333 Ludlow Street, Stamford, CT, 06902, USA.
Li L; Sema4, a Mount Sinai Venture, 333 Ludlow Street, Stamford, CT, 06902, USA.; Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Pl, New York, NY, 10029, USA.
Redfern A; Sema4, a Mount Sinai Venture, 333 Ludlow Street, Stamford, CT, 06902, USA.
Jappe W; Sema4, a Mount Sinai Venture, 333 Ludlow Street, Stamford, CT, 06902, USA.
Liu Z; Sema4, a Mount Sinai Venture, 333 Ludlow Street, Stamford, CT, 06902, USA.
Goldsweig H; Sema4, a Mount Sinai Venture, 333 Ludlow Street, Stamford, CT, 06902, USA.
Yadav KK; Sema4, a Mount Sinai Venture, 333 Ludlow Street, Stamford, CT, 06902, USA.
Hahner N; Sema4, a Mount Sinai Venture, 333 Ludlow Street, Stamford, CT, 06902, USA.
Dietz M; Sema4, a Mount Sinai Venture, 333 Ludlow Street, Stamford, CT, 06902, USA.
Zimmerman M; Sema4, a Mount Sinai Venture, 333 Ludlow Street, Stamford, CT, 06902, USA.
Prentice T; Sema4, a Mount Sinai Venture, 333 Ludlow Street, Stamford, CT, 06902, USA.
Newman S; Sema4, a Mount Sinai Venture, 333 Ludlow Street, Stamford, CT, 06902, USA.
Veluswamy R; Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Pl, New York, NY, 10029, USA.
Wisnivesky J; Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Pl, New York, NY, 10029, USA.
Hirsch FR; Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Pl, New York, NY, 10029, USA.
Oh WK; Sema4, a Mount Sinai Venture, 333 Ludlow Street, Stamford, CT, 06902, USA.; Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Pl, New York, NY, 10029, USA.
Li SD; Sema4, a Mount Sinai Venture, 333 Ludlow Street, Stamford, CT, 06902, USA.; Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Pl, New York, NY, 10029, USA.
Schadt EE; Sema4, a Mount Sinai Venture, 333 Ludlow Street, Stamford, CT, 06902, USA.; Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Pl, New York, NY, 10029, USA.
Chen R; Sema4, a Mount Sinai Venture, 333 Ludlow Street, Stamford, CT, 06902, USA.; Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Pl, New York, NY, 10029, USA.
Pokaż więcej
Źródło :
The oncologist [Oncologist] 2021 Apr 07. Date of Electronic Publication: 2021 Apr 07.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Adherence to NCCN ALK testing guidelines for patients with advanced non-small cell lung cancer in US Community Medical Centers.
Autorzy :
Bernicker EH; Cancer Center, Houston Methodist Hospital, Houston, TX.
Xiao Y; Roche Diagnostics Information Solutions, Pleasanton, CA.; AstraZeneca R&D, China.
Abraham A; Genesis Research, Hoboken.
Yang B; Roche Diagnostics Information Solutions, Pleasanton, CA.
Croix D; Roche Diagnostics, Indianapolis, IN.
Redpath S; Roche Diagnostics, Indianapolis, IN.
Engstrom-Melnyk J; Roche Diagnostics, Indianapolis, IN.; AstraZeneca Pharmaceuticals LP, Gaithersburg, MD.
Shah R; Roche Diagnostics Information Solutions, Pleasanton, CA.
Madala J; Roche Diagnostics Information Solutions, Pleasanton, CA.
Allen TC; University of Mississippi Medical Center, Jackson, MS.
Pokaż więcej
Źródło :
The oncologist [Oncologist] 2021 Apr 06. Date of Electronic Publication: 2021 Apr 06.
Typ publikacji :
Letter
Opinia redakcyjna
Tytuł :
Patients' and Oncologists' Knowledge and Expectations Regarding Tumour Multigene Next Generation Sequencing: A Narrative Review.
Autorzy :
Shirdarreh M; Division of Medical Oncology, Sunnybrook Health Sciences Centre, 2075 , Bayview Avenue, Toronto, Ontario, M4N 3M5, Canada.
Aziza O; Division of Medical Oncology, Sunnybrook Health Sciences Centre, 2075 , Bayview Avenue, Toronto, Ontario, M4N 3M5, Canada.
Pezo RC; Division of Medical Oncology, Sunnybrook Health Sciences Centre, 2075 , Bayview Avenue, Toronto, Ontario, M4N 3M5, Canada.; Faculty of Medicine, University of Toronto, 1 King's College Cir, Toronto, ON, M5S 1A8, Canada.
Jerzak KJ; Division of Medical Oncology, Sunnybrook Health Sciences Centre, 2075 , Bayview Avenue, Toronto, Ontario, M4N 3M5, Canada.; Faculty of Medicine, University of Toronto, 1 King's College Cir, Toronto, ON, M5S 1A8, Canada.
Warner E; Division of Medical Oncology, Sunnybrook Health Sciences Centre, 2075 , Bayview Avenue, Toronto, Ontario, M4N 3M5, Canada.; Faculty of Medicine, University of Toronto, 1 King's College Cir, Toronto, ON, M5S 1A8, Canada.
Pokaż więcej
Źródło :
The oncologist [Oncologist] 2021 Apr 06. Date of Electronic Publication: 2021 Apr 06.
Typ publikacji :
Journal Article; Review
Czasopismo naukowe
Tytuł :
Patient burden with current surveillance paradigm and factors associated with interest in altered surveillance for early stage HPV-related oropharyngeal cancer.
Autorzy :
Gharzai LA; Department of Radiation Oncology, University of Michigan.; Center for Bioethics and Social Sciences in Medicine, University of Michigan.
Burger N; Department of Otolaryngology, University of Michigan.
Li P; Department of Biostatistics, University of Michigan.
Jaworski EM; Department of Radiation Oncology, University of Michigan.
Henderson C; Department of Radiation Oncology, University of Michigan.
Spector M; Department of Otolaryngology, University of Michigan.
Rosko A; Department of Otolaryngology, University of Michigan.
Chen MM; Department of Otolaryngology, University of Michigan.
Prince ME; Department of Otolaryngology, University of Michigan.
Bradford CR; Department of Otolaryngology, University of Michigan.
Malloy KM; Department of Otolaryngology, University of Michigan.
Stucken CL; Department of Otolaryngology, University of Michigan.
Swiecicki P; Department of Medical Oncology, University of Michigan.
Worden F; Department of Medical Oncology, University of Michigan.
Schipper MJ; Department of Biostatistics, University of Michigan.
Schonewolf CA; Department of Radiation Oncology, University of Michigan.
Shah J; Department of Radiation Oncology, University of Michigan.
Jagsi R; Department of Radiation Oncology, University of Michigan.; Center for Bioethics and Social Sciences in Medicine, University of Michigan.
Chinn S; Department of Otolaryngology, University of Michigan.
Shuman A; Department of Otolaryngology, University of Michigan.
Casper K; Department of Otolaryngology, University of Michigan.
Mierzwa ML; Department of Radiation Oncology, University of Michigan.
Pokaż więcej
Źródło :
The oncologist [Oncologist] 2021 Apr 06. Date of Electronic Publication: 2021 Apr 06.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Letter to the Editor regarding article published by Rugo et. al.
Autorzy :
Badaoui S; College of Medicine and Public Health, Flinders University, Adelaide, Australia.
Rowland A; College of Medicine and Public Health, Flinders University, Adelaide, Australia.
Sorich MJ; College of Medicine and Public Health, Flinders University, Adelaide, Australia.
Hopkins AM; College of Medicine and Public Health, Flinders University, Adelaide, Australia.
Pokaż więcej
Źródło :
The oncologist [Oncologist] 2021 Apr 05. Date of Electronic Publication: 2021 Apr 05.
Typ publikacji :
Letter
Opinia redakcyjna
Tytuł :
Immune-checkpoint inhibitors for advanced hepatocellular carcinoma: a synopsis of response rates.
Autorzy :
Shek D; Blacktown Clinical School, Western Sydney University, Sydney, New South Wales, Australia.; Storr Liver Centre, Westmead Institute for Medical Research, Sydney, New South Wales, Australia.; Blacktown Hospital, Sydney, New South Wales, Australia.
Read SA; Blacktown Clinical School, Western Sydney University, Sydney, New South Wales, Australia.; Storr Liver Centre, Westmead Institute for Medical Research, Sydney, New South Wales, Australia.; Blacktown Hospital, Sydney, New South Wales, Australia.
Nagrial A; Blacktown Hospital, Sydney, New South Wales, Australia.; Westmead Hospital, Sydney, New South Wales, Australia.; Westmead Clinical School, University of Sydney, Sydney, New South Wales, Australia.
Carlino MS; Blacktown Hospital, Sydney, New South Wales, Australia.; Westmead Hospital, Sydney, New South Wales, Australia.; Westmead Clinical School, University of Sydney, Sydney, New South Wales, Australia.; Melanoma Institute Australia, Sydney, New South Wales, Australia.
Gao B; Blacktown Hospital, Sydney, New South Wales, Australia.; Westmead Hospital, Sydney, New South Wales, Australia.
George J; Storr Liver Centre, Westmead Institute for Medical Research, Sydney, New South Wales, Australia.; Westmead Hospital, Sydney, New South Wales, Australia.; Westmead Clinical School, University of Sydney, Sydney, New South Wales, Australia.
Ahlenstiel G; Blacktown Clinical School, Western Sydney University, Sydney, New South Wales, Australia.; Storr Liver Centre, Westmead Institute for Medical Research, Sydney, New South Wales, Australia.; Westmead Hospital, Sydney, New South Wales, Australia.; Westmead Clinical School, University of Sydney, Sydney, New South Wales, Australia.
Pokaż więcej
Źródło :
The oncologist [Oncologist] 2021 Apr 05. Date of Electronic Publication: 2021 Apr 05.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Muscle Loss is Associated with Overall Survival in Patients with Metastatic Colorectal Cancer Independent of Tumor Mutational Status and Weight Loss.
Autorzy :
Cand TDB; Department of Radiology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.; Department of Radiology, Division of Thoracic Imaging and Intervention, Massachusetts General Hospital & Harvard Medical School, Boston, Massachusetts, USA.
Roeland EJ; Department of Medicine, Division of Hematology & Oncology, Massachusetts General Hospital Cancer Center & Harvard Medical School, Boston, Massachusetts, USA.
Horick NK; Department of Statistics, Massachusetts General Hospital & Harvard Medical School, Boston, Massachusetts, USA.
Van Seventer EE; Department of Medicine, Division of Hematology & Oncology, Massachusetts General Hospital Cancer Center & Harvard Medical School, Boston, Massachusetts, USA.
El-Jawahri A; Department of Medicine, Division of Hematology & Oncology, Massachusetts General Hospital Cancer Center & Harvard Medical School, Boston, Massachusetts, USA.
Cand AST; Department of Radiology, Division of Thoracic Imaging and Intervention, Massachusetts General Hospital & Harvard Medical School, Boston, Massachusetts, USA.
Johnson PC; Department of Medicine, Division of Hematology & Oncology, Massachusetts General Hospital Cancer Center & Harvard Medical School, Boston, Massachusetts, USA.
Kanter KN; Department of Medicine, Division of Hematology & Oncology, Massachusetts General Hospital Cancer Center & Harvard Medical School, Boston, Massachusetts, USA.
Fish MG; Department of Medicine, Division of Hematology & Oncology, Massachusetts General Hospital Cancer Center & Harvard Medical School, Boston, Massachusetts, USA.
Cand JPM; Department of Radiology, Division of Thoracic Imaging and Intervention, Massachusetts General Hospital & Harvard Medical School, Boston, Massachusetts, USA.; School of Medicine, RWTH Aachen University, Aachen, Germany.
Bridge CP; MGH and BWH Center for Clinical Data Science, Boston, Massachusetts, USA.
Temel JS; Department of Medicine, Division of Hematology & Oncology, Massachusetts General Hospital Cancer Center & Harvard Medical School, Boston, Massachusetts, USA.
Corcoran RB; Department of Medicine, Division of Hematology & Oncology, Massachusetts General Hospital Cancer Center & Harvard Medical School, Boston, Massachusetts, USA.
Nipp RD; Department of Medicine, Division of Hematology & Oncology, Massachusetts General Hospital Cancer Center & Harvard Medical School, Boston, Massachusetts, USA.
Fintelmann FJ; Department of Radiology, Division of Thoracic Imaging and Intervention, Massachusetts General Hospital & Harvard Medical School, Boston, Massachusetts, USA.
Pokaż więcej
Źródło :
The oncologist [Oncologist] 2021 Apr 05. Date of Electronic Publication: 2021 Apr 05.
Typ publikacji :
Journal Article
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies